Search
NeOnc Technologies Holdings Inc
NTHIAdd to Watchlist
4.420USD
-0.040-0.90%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
97.20MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-0.90%
5 Days
-2.00%
1 Month
-3.49%
6 Months
-50.23%
Year to Date
-46.55%
1 Year
-16.45%
Key Figures
4.460Open
4.460High
90.14KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.41%Turnover Ratio
4.460Prev. Close
4.205Low
307.43KTurnover
LossP/E Static
-5.55P/B
0.00%Div Yield TTM
-1991.59%ROA
12.99052wk High
2.51Volume Ratio
-11.90MNet Profit
21.99MShares
-3.2036EPS TTM
--Beta
--ROE
3.20052wk Low
5.72%Amplitude
100.00%Gross Margin
97.20MMarket Cap
0.38Reward/Risk
6.74%Risk Rate
TradingKey Stock Score of NeOnc Technologies Holdings Inc
Currency: USD Updated: 2026-07-01Key Insights
NeOnc Technologies Holdings Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 122 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 16.00.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
NeOnc Technologies Holdings Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
NeOnc Technologies Holdings Inc Highlights
StrengthsRisks
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on establishing treatments for intracranial malignancies, such as aggressive cancers located in the brain. It is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. It is developing novel drug delivery methods to be used in combination with novel drug candidates. The Company has two lead products in development: NEO100 and NEO212. NEO100 is a purified form of perillyl acid (POH) which is administered to brain cancer patients via intranasal delivery. NEO212 is a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol. NEO212 is undergoing development towards intranasal application specifically for patients with uncontrolled brain metastases derived from peripheral tumors (lung, breast, skin, and others).
Growing
The company is in a growing phase, with the latest annual income totaling USD 39.99K.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 39.99K.
Overvalued
The company’s latest PE is -1.39, at a high 3-year percentile range.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
16.000
Target Price
+261.17%
Upside Space
NeOnc Technologies Holdings Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
NeOnc Technologies Holdings Inc Info
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on establishing treatments for intracranial malignancies, such as aggressive cancers located in the brain. It is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. It is developing novel drug delivery methods to be used in combination with novel drug candidates. The Company has two lead products in development: NEO100 and NEO212. NEO100 is a purified form of perillyl acid (POH) which is administered to brain cancer patients via intranasal delivery. NEO212 is a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol. NEO212 is undergoing development towards intranasal application specifically for patients with uncontrolled brain metastases derived from peripheral tumors (lung, breast, skin, and others).
Ticker SymbolNTHI
CompanyNeOnc Technologies Holdings Inc
CEOHeshmatpour (Amir F)
Websitehttps://neonc.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+2.95%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
53071.700
+229.200 (+0.43%)
29427.700
+116.300 (+0.40%)
7499.100
+27.600 (+0.37%)
14827.000
+24.000 (+0.16%)
68979.000
+831.000 (+1.22%)
6372.300
+19.500 (+0.31%)
68.423
+0.079 (+0.12%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4188.590
+66.680 (+1.62%)
FAQs
What is the current price of NeOnc Technologies Holdings Inc (NTHI)?
The current price of NeOnc Technologies Holdings Inc (NTHI) is 4.42.
What is the symbol of NeOnc Technologies Holdings Inc?
The ticker symbol of NeOnc Technologies Holdings Inc is NTHI.
What is the 52-week high of NeOnc Technologies Holdings Inc?
The 52-week high of NeOnc Technologies Holdings Inc is 12.99.
What is the 52-week low of NeOnc Technologies Holdings Inc?
The 52-week low of NeOnc Technologies Holdings Inc is 3.20.
What is the market capitalization of NeOnc Technologies Holdings Inc?
The market capitalization of NeOnc Technologies Holdings Inc is 97.20M.
Is NeOnc Technologies Holdings Inc (NTHI) currently rated as Buy, Hold, or Sell?
According to analysts, NeOnc Technologies Holdings Inc (NTHI) has an overall rating of Buy, with a price target of 16.00.
What is the Earnings Per Share (EPS TTM) of NeOnc Technologies Holdings Inc (NTHI)?
The Earnings Per Share (EPS TTM) of NeOnc Technologies Holdings Inc (NTHI) is -3.20.